Please assess the completion status of the following clinical trial:

Trial Title: Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven diagnosis of prostate cancer~* Evidence of PSA progression despite castrate levels of testosterone (\<50 ng/dL) following orchiectomy or during therapy with luteinizing hormone releasing hormone agonists (LHRH-a)~* Patients with non-metastatic or stable metastatic disease~* Chromogranin A elevation above normal range (confirmed by a second evaluation at least 1 week later) \[cut off levels will be \> 20 U/L for enzyme linked immunosorbent (ELISA) assay and \> 100 ng/ml for immunoradiometric (IRMA) assay\]~Exclusion Criteria:~* Patients who according to the investigator opinion are candidates to be treated immediately with chemotherapy (e.g. docetaxel)~* First line treatment with antiandrogen in monotherapy~* Visceral metastasis~* Previous or concomitant treatment with a somatostatin analogue

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: OTHER): None
- Arm B (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).